Clinical Trials Logo

Clinical Trial Summary

The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.


Clinical Trial Description

The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in patients with severe acute kidney injury or sepsis, compared with standard membranes. Based on this benefit, the use of oXiris may confer better outcomes than other membranes. The patient outcomes include cardiovascular, respiratory, renal, and overall survivals, but this information of oXiris are insufficient. Although cytokine and endotoxin removal rates are great in oXiris, the beneficial effects on the hard outcomes are needed to use oXiris in real clinical practice. The inflammatory and cardiovascular systems have intensive crosstalk, and thus if there are remission in inflammatory process, the patients can have hemodynamic stability. Regarding this, the investigators would like to compare the hemodynamic stability between oXiris and other standard membrane such as polysulfone, using our new real-time monitoring registry. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05575024
Study type Observational
Source Seoul National University Hospital
Contact Seung Seok Han, M.D.
Phone 82-2-2072-4785
Email hansway7@snu.ac.kr
Status Recruiting
Phase
Start date January 1, 2024
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05114057 - Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI N/A
Active, not recruiting NCT05507437 - Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury Phase 2
Terminated NCT04411472 - (Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI Phase 3
Recruiting NCT05939245 - Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group N/A
Recruiting NCT06295393 - Renin Angiotensin Aldosterone System In Septic Kids
Completed NCT04633746 - Plasma Endostatin Predicts Outcome of Septic AKI
Recruiting NCT05996835 - Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI) Phase 2
Completed NCT05060679 - Presepsin:Gelsolin Ratio in Sepsis-related Organ Dysfunction
Completed NCT04968262 - Urinary Actin, as a Potential Marker of Sepsis-related Acute Kidney Injury
Not yet recruiting NCT05559086 - N/LP Ratio as Predictor of Mortality in Septic AKI Patients
Recruiting NCT05982340 - Endogenous Lithium Clearance in Acute Kidney Injury